The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings

BACKGROUND: Sacubitril/valsartan, the first agent to be approved in a new class of drugs called angiotensin receptor neprilysin inhibitors (ARNIs), has been shown to reduce cardiovascular mortality and morbidity compared to enalapril in outpatient subjects with chronic heart failure (HF) and reduced...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazza, Alberto, Townsend, Danyelle M., Torin, Gioia, Schiavon, Laura, Camerotto, Alessandro, Rigatelli, Gianluca, Cuppini, Stefano, Minuz, Pietro, Rubello, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963534/
https://www.ncbi.nlm.nih.gov/pubmed/34321170
http://dx.doi.org/10.1016/j.biopha.2020.110596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963534/
https://www.ncbi.nlm.nih.gov/pubmed/34321170
http://dx.doi.org/10.1016/j.biopha.2020.110596

Ejemplares similares